The Trump administration is indefinitely delaying a Medicare pilot program to cover weight-loss drugs, following concerns from health insurance companies. The five-year experiment, BALANCE, would have involved private Medicare insurers paying for drugs like Zepbound and Wegovy as a regular benefit. However, Medicare will still cover these drugs through a transitional program, starting in July and running through 2027. This decision is a setback for the administration after President Trump promised deals with Eli Lilly and Novo Nordisk to reduce prices on GLP-1 drugs in exchange for access to a new pool of patients. The transitional program means seniors can still receive expanded coverage and participating Medicare drug plans don't have to take financial risk.